Roivant Sciences is trading at $33.50, down 8.19% in pre-market; no fresh company announcement explains the decline. - Latest major company news was positive Phase 3 brepocitinib data announced October 21; Priovant plans to seek expanded approval in the first half of 2027. - Immunovant CEO Eric Venker disclosed a planned 200,000-share sale on October 20, but available reports do not establish it caused the move. - Major indices were mixed and near flat, offering no clear broad-market explanation.